BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 10929020)

  • 1. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
    Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Mordini N; Berisso G; Bregante S; Frassoni F; Sessarego M; Fugazza G; Di Stefano F; Pitto A; Bacigalupo A
    Br J Haematol; 2000 Jun; 109(4):716-21. PubMed ID: 10929020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
    Bacigalupo A; Van Lint MT; Valbonesi M; Lercari G; Carlier P; Lamparelli T; Gualandi F; Occhini D; Bregante S; Valeriani A; Piaggio G; Pitto A; Benvenuto F; Figari O; De Stefano G; Caimo A; Sessarego M
    Blood; 1996 Jul; 88(1):353-7. PubMed ID: 8704195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.
    Lamparelli T; van Lint MT; Gualandi F; Raiola AM; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Bregante S; Berisso G; Dominietto A; Di Grazia C; Bruno B; Sessarego M; Casarino L; Verdiani S; Bacigalupo A
    Bone Marrow Transplant; 2000 Dec; 26(12):1305-11. PubMed ID: 11223970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
    Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial.
    Devetten MP; Qazilbash MH; Beall CL; Bunner P; Weisenborn R; Lynch JP; Ericson SG
    Bone Marrow Transplant; 2004 Oct; 34(7):577-80. PubMed ID: 15286685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients aged 50 years and over.
    Fujimaki K; Tanaka M; Takasaki H; Hyo R; Kawano T; Sakai R; Fujita H; Fujisawa S; Kanamori H; Maruta A; Ishigatsubo Y
    Intern Med; 2008; 47(5):379-83. PubMed ID: 18310967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Eder S; Labopin M; Arcese W; Or R; Majolino I; Bacigalupo A; de Rosa G; Volin L; Beelen D; Veelken H; Schaap NP; Kuball J; Cornelissen J; Nagler A; Mohty M;
    Eur J Haematol; 2016 Jan; 96(1):90-7. PubMed ID: 25807864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF.
    Chen HR; Ji SQ; Wang HX; Yan HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):340-6. PubMed ID: 12513770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft.
    di Grazia C; Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Berisso G; Bregante S; Dominietto A; Mordini N; Bruno B; Frassoni F; Bacigalupo A
    Haematologica; 2001 Jun; 86(6):646-51. PubMed ID: 11418375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen.
    Khoury H; Adkins D; Brown R; Pence H; Vij R; Goodnough LT; Westervelt P; Trinkaus K; Lin HS; DiPersio Y
    Biol Blood Marrow Transplant; 2001; 7(6):352-8. PubMed ID: 11464978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Eder S; Beohou E; Labopin M; Sanz J; Finke J; Arcese W; Or R; Bonifazi F; Aljurf M; Socié G; Passweg J; Giebel S; Mohty M; Nagler A
    Am J Hematol; 2017 Jan; 92(1):18-22. PubMed ID: 27673280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.
    Rosales F; Naparstek E; Varadi G; Or R; Slavin S; Nagler A
    Leuk Res; 1999 Oct; 23(10):947-52. PubMed ID: 10573141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings.
    Zecca M; Pession A; Messina C; Bonetti F; Favre C; Prete A; Cesaro S; Porta F; Mazzarino I; Giorgiani G; Rondelli R; Locatelli F
    J Clin Oncol; 1999 Jun; 17(6):1838-46. PubMed ID: 10561223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.